

CLAIMS AFTER AMENDMENT**In the Claims:**

1-59 Cancelled.

60. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 353 nucleotides.

61. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 586 nucleotides.

62. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lamda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 353 nucleotides.

63. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lamda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 586 nucleotides.

64. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 353 nucleotides.

65. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 586 nucleotides.

66. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 353 nucleotides.

67. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 586 nucleotides.

68. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figures 57, wherein said polynucleotide has a maximum length of 353 nucleotides.

69. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the

nucleotide sequence in Figure 57, wherein said polynucleotide has a maximum length of 586 nucleotides.

70. (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.
71. (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.
72. (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.
73. (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.
74. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 10 nucleotides.

75. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 12 nucleotides.
76. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 15 nucleotides.
77. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 20 nucleotides.
78. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide has a maximum length of 161 nucleotides.
79. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide has a maximum length of 161 nucleotides.
80. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide has a maximum length of 161 nucleotides.
81. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 161 nucleotides.
82. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide has a maximum length of 161 nucleotides.
83. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide has a maximum length of 108 nucleotides.
84. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide has a maximum length of 108 nucleotides.

85. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide has a maximum length of 108 nucleotides.
86. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 108 nucleotides.
87. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide has a maximum length of 108 nucleotides
88. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is single stranded.
89. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is single stranded.
90. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is single stranded.
91. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is single stranded.
92. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is single stranded.
93. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is single stranded.
94. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is single stranded.

95. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is single stranded.
96. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is single stranded.
97. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is single stranded.
98. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is single stranded.
99. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is single stranded.
100. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is single stranded.
101. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is single stranded.
102. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is single stranded.
103. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is DNA.
104. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is DNA.

105. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is DNA.

106. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is DNA.

107. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is DNA.

108. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is DNA.

109. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is DNA.

110. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is DNA.

111. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is DNA.

112. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is DNA.

113. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is DNA.

114. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is DNA.

115. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is DNA.

116. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is DNA.

117. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is DNA.

118. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is DNA.

119. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is DNA.

120. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is DNA.

121. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is DNA.

122. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is DNA.

123. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is DNA.

124. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is DNA.

125. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is DNA.

126. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is DNA.

127. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is DNA.

128. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is DNA.

129. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is DNA.

130. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is DNA.

131. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is DNA.

132. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is DNA.

133. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is labeled.

134. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is labeled.

135. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is labeled.

136. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is labeled.

137. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is labeled.

138. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is labeled.

139. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is labeled.

140. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is labeled.

141. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is labeled.

142. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is labeled.

143. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is labeled.

144. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is labeled.

145. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is labeled.

146. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is labeled.

147. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is labeled.

148. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is labeled.

149. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is labeled.

150. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is labeled.

151. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is labeled.

152. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is labeled.

153. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is labeled.

154. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is labeled.

155. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is labeled.

156. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is labeled.

157. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is labeled.

158. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is labeled.

159. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is labeled.

160. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is labeled.

161. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is labeled.

162. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is labeled.

163. (Previously Presented) A polynucleotide according to claim 103 wherein said polynucleotide is labeled.

164. (Previously Presented) A polynucleotide according to claim 104 wherein said polynucleotide is labeled.

165. (Previously Presented) A polynucleotide according to claim 105 wherein said polynucleotide is labeled.

166. (Previously Presented) A polynucleotide according to claim 106 wherein said polynucleotide is labeled.

167. (Previously Presented) A polynucleotide according to claim 107 wherein said polynucleotide is labeled.

168. (Previously Presented) A polynucleotide according to claim 108 wherein said polynucleotide is labeled.

169. (Previously Presented) A polynucleotide according to claim 109 wherein said polynucleotide is labeled.

170. (Previously Presented) A polynucleotide according to claim 110 wherein said polynucleotide is labeled.

171. (Previously Presented) A polynucleotide according to claim 111 wherein said polynucleotide is labeled.

172. (Previously Presented) A polynucleotide according to claim 112 wherein said polynucleotide is labeled.

173. (Previously Presented) A polynucleotide according to claim 113 wherein said polynucleotide is labeled.

174. (Previously Presented) A polynucleotide according to claim 114 wherein said polynucleotide is labeled.

175. (Previously Presented) A polynucleotide according to claim 115 wherein said polynucleotide is labeled.

176. (Previously Presented) A polynucleotide according to claim 116 wherein said polynucleotide is labeled.

177. (Previously Presented) A polynucleotide according to claim 117 wherein said polynucleotide is labeled.

178. (Previously Presented) A polynucleotide according to claim 118 wherein said polynucleotide is labeled.

179. (Previously Presented) A polynucleotide according to claim 119 wherein said polynucleotide is labeled.

180. (Previously Presented) A polynucleotide according to claim 120 wherein said polynucleotide is labeled.

181. (Previously Presented) A polynucleotide according to claim 121 wherein said polynucleotide is labeled.

182. (Previously Presented) A polynucleotide according to claim 122 wherein said polynucleotide is labeled.

183. (Previously Presented) A polynucleotide according to claim 123 wherein said polynucleotide is labeled.

184. (Previously Presented) A polynucleotide according to claim 124 wherein said polynucleotide is labeled.

185. (Previously Presented) A polynucleotide according to claim 125 wherein said polynucleotide is labeled.
186. (Previously Presented) A polynucleotide according to claim 126 wherein said polynucleotide is labeled.
187. (Previously Presented) A polynucleotide according to claim 127 wherein said polynucleotide is labeled.
188. (Previously Presented) A polynucleotide according to claim 128 wherein said polynucleotide is labeled.
189. (Previously Presented) A polynucleotide according to claim 129 wherein said polynucleotide is labeled.
190. (Previously Presented) A polynucleotide according to claim 130 wherein said polynucleotide is labeled.
191. (Previously Presented) A polynucleotide according to claim 131 wherein said polynucleotide is labeled.
192. (Previously Presented) A polynucleotide according to claim 132 wherein said polynucleotide is labeled.
193. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is RNA.
194. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is RNA.

195. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is RNA.

196. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is RNA.

197. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is RNA.

198. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is RNA.

199. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is RNA.

200. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is RNA.

201. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is RNA.

202. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is RNA.

203. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is RNA.

204. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is RNA.

205. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is RNA.

206. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is RNA.

207. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is RNA.

208. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is RNA.

209. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is RNA.

210. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is RNA.

211. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is RNA.

212. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is RNA.

213. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is RNA.

214. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is RNA.

215. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is RNA.

216. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is RNA.

217. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is RNA.

218. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is RNA.

219. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is RNA.

220. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is RNA.

221. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is RNA.

222. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is RNA.

223. (Previously Presented) A polynucleotide according to claim 193 wherein said polynucleotide is labeled.

224. (Previously Presented) A polynucleotide according to claim 194 wherein said polynucleotide is labeled.

225. (Previously Presented) A polynucleotide according to claim 195 wherein said polynucleotide is labeled.

226. (Previously Presented) A polynucleotide according to claim 196 wherein said polynucleotide is labeled.

227. (Previously Presented) A polynucleotide according to claim 197 wherein said polynucleotide is labeled.

228. (Previously Presented) A polynucleotide according to claim 198 wherein said polynucleotide is labeled.

229. (Previously Presented) A polynucleotide according to claim 199 wherein said polynucleotide is labeled.

230. (Previously Presented) A polynucleotide according to claim 200 wherein said polynucleotide is labeled.

231. (Previously Presented) A polynucleotide according to claim 201 wherein said polynucleotide is labeled.

232. (Previously Presented) A polynucleotide according to claim 202 wherein said polynucleotide is labeled.

233. (Previously Presented) A polynucleotide according to claim 203 wherein said polynucleotide is labeled.

234. (Previously Presented) A polynucleotide according to claim 204 wherein said polynucleotide is labeled.

235. (Previously Presented) A polynucleotide according to claim 205 wherein said polynucleotide is labeled.

236. (Previously Presented) A polynucleotide according to claim 206 wherein said polynucleotide is labeled.

237. (Previously Presented) A polynucleotide according to claim 207 wherein said polynucleotide is labeled.

238. (Previously Presented) A polynucleotide according to claim 208 wherein said polynucleotide is labeled.

239. (Previously Presented) A polynucleotide according to claim 209 wherein said polynucleotide is labeled.

240. (Previously Presented) A polynucleotide according to claim 210 wherein said polynucleotide is labeled.

241. (Previously Presented) A polynucleotide according to claim 211 wherein said polynucleotide is labeled.

242. (Previously Presented) A polynucleotide according to claim 212 wherein said polynucleotide is labeled.

243. (Previously Presented) A polynucleotide according to claim 213 wherein said polynucleotide is labeled.

244. (Previously Presented) A polynucleotide according to claim 214 wherein said polynucleotide is labeled.

245. (Previously Presented) A polynucleotide according to claim 215 wherein said polynucleotide is labeled.

246. (Previously Presented) A polynucleotide according to claim 216 wherein said polynucleotide is labeled.

247. (Previously Presented) A polynucleotide according to claim 217 wherein said polynucleotide is labeled.

248. (Previously Presented) A polynucleotide according to claim 218 wherein said polynucleotide is labeled.

249. (Previously Presented) A polynucleotide according to claim 219 wherein said polynucleotide is labeled.

250. (Previously Presented) A polynucleotide according to claim 220 wherein said polynucleotide is labeled.

251. (Previously Presented) A polynucleotide according to claim 221 wherein said polynucleotide is labeled.

252. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is an oligonucleotide.

253. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is an oligonucleotide.

254. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is an oligonucleotide.

255. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is an oligonucleotide.

256. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is an oligonucleotide.

257. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is an oligonucleotide.

258. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is an oligonucleotide.

259. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is an oligonucleotide.

260. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is an oligonucleotide.

261. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is an oligonucleotide.

262. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is an oligonucleotide.

263. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is an oligonucleotide.

264. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is an oligonucleotide.

265. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is an oligonucleotide.

266. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is an oligonucleotide.

267. (Previously Presented) A polynucleotide according to claim 222 wherein said polynucleotide is labeled.

268. (Previously Presented) An oligonucleotide according to claim 252 wherein said oligonucleotide is labeled.

269. (Previously Presented) An oligonucleotide according to claim 253 wherein said oligonucleotide is labeled.

270. (Previously Presented) An oligonucleotide according to claim 254 wherein said oligonucleotide is labeled.

271. (Previously Presented) An oligonucleotide according to claim 255 wherein said oligonucleotide is labeled.

272. (Previously Presented) An oligonucleotide according to claim 256 wherein said oligonucleotide is labeled.

273. (Previously Presented) An oligonucleotide according to claim 257 wherein said oligonucleotide is labeled.

274. (Previously Presented) An oligonucleotide according to claim 258 wherein said oligonucleotide is labeled.

275. (Previously Presented) An oligonucleotide according to claim 259 wherein said oligonucleotide is labeled.

276. (Previously Presented) An oligonucleotide according to claim 260 wherein said oligonucleotide is labeled.

277. (Previously Presented) An oligonucleotide according to claim 261 wherein said oligonucleotide is labeled.

278. (Previously Presented) An oligonucleotide according to claim 262 wherein said oligonucleotide is labeled.

279. (Previously Presented) An oligonucleotide according to claim 263 wherein said oligonucleotide is labeled.

280. (Previously Presented) An oligonucleotide according to claim 264 wherein said oligonucleotide is labeled.

281. (Previously Presented) An oligonucleotide according to claim 265 wherein said oligonucleotide is labeled.

282. (Previously Presented) An oligonucleotide according to claim 266 wherein said oligonucleotide is labeled.

283. (Previously Presented) A polynucleotide according to claim 267 wherein said polynucleotide is an oligonucleotide.

284. (Previously Presented) A composition comprising the polynucleotide of any of claims 60-73 wherein said polynucleotide is substantially isolated.

285. (Previously Presented) A composition comprising the polynucleotide of claim 74 wherein said polynucleotide is substantially isolated.

286. (Previously Presented) A composition comprising the polynucleotide of claim 75 wherein said polynucleotide is substantially isolated.

287. (Previously Presented) A composition comprising the polynucleotide of claim 76 wherein said polynucleotide is substantially isolated.

288. (Previously Presented) A composition comprising the polynucleotide of claim 77 wherein said polynucleotide is substantially isolated.

289. (Previously Presented) A composition comprising the polynucleotide of claim 78 wherein said polynucleotide is substantially isolated.

290. (Previously Presented) A composition comprising the polynucleotide of claim 79 wherein said polynucleotide is substantially isolated.

291. (Previously Presented) A composition comprising the polynucleotide of claim 80 wherein said polynucleotide is substantially isolated.

292. (Previously Presented) A composition comprising the polynucleotide of claim 81 wherein said polynucleotide is substantially isolated.

293. (Previously Presented) A composition comprising the polynucleotide of claim 82 wherein said polynucleotide is substantially isolated.

294. (Previously Presented) A composition comprising the polynucleotide of claim 83 wherein said polynucleotide is substantially isolated.

295. (Previously Presented) A composition comprising the polynucleotide of claim 84 wherein said polynucleotide is substantially isolated.

296. (Previously Presented) A composition comprising the polynucleotide of claim 85 wherein said polynucleotide is substantially isolated.

297. (Previously Presented) A composition comprising the polynucleotide of claim 86 wherein said polynucleotide is substantially isolated.

298. (Previously Presented) A composition comprising the polynucleotide of claim 87 wherein said polynucleotide is substantially isolated.

299. (Previously Presented) A composition comprising the polynucleotide of claim 88 wherein said polynucleotide is substantially isolated.

300. (Previously Presented) A composition comprising the polynucleotide of claim 89 wherein said polynucleotide is substantially isolated.

301. (Previously Presented) A composition comprising the polynucleotide of claim 90 wherein said polynucleotide is substantially isolated.

302. (Previously Presented) A composition comprising the polynucleotide of claim 91 wherein said polynucleotide is substantially isolated.

303. (Previously Presented) A composition comprising the polynucleotide of claim 92 wherein said polynucleotide is substantially isolated.

304. (Previously Presented) A composition comprising the polynucleotide of claim 93 wherein said polynucleotide is substantially isolated.

305. (Previously Presented) A composition comprising the polynucleotide of claim 94 wherein said polynucleotide is substantially isolated.
306. (Previously Presented) A composition comprising the polynucleotide of claim 95 wherein said polynucleotide is substantially isolated.
307. (Previously Presented) A composition comprising the polynucleotide of claim 96 wherein said polynucleotide is substantially isolated.
308. (Previously Presented) A composition comprising the polynucleotide of claim 97 wherein said polynucleotide is substantially isolated.
309. (Previously Presented) A composition comprising the polynucleotide of claim 98 wherein said polynucleotide is substantially isolated.
310. (Previously Presented) A composition comprising the polynucleotide of claim 99 wherein said polynucleotide is substantially isolated.
311. (Previously Presented) A composition comprising the polynucleotide of claim 100 wherein said polynucleotide is substantially isolated.
312. (Previously Presented) A composition comprising the polynucleotide of claim 101 wherein said polynucleotide is substantially isolated.
313. (Previously Presented) A composition comprising the polynucleotide of claim 102 wherein said polynucleotide is substantially isolated.
314. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of any of claims 60-73 in a suitable package.

315. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 74 in a suitable package.

316. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 75 in a suitable package.

317. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 76 in a suitable package.

318. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 77 in a suitable package.

319. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 78 in a suitable package.

320. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 79 in a suitable package.

321. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 80 in a suitable package.

322. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 81 in a suitable package.

323. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 82 in a suitable package.

324. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 83 in a suitable package.

325. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 84 in a suitable package.

326. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 85 in a suitable package.

327. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 86 in a suitable package.

328. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 87 in a suitable package.

329. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 88 in a suitable package.

330. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 95 in a suitable package.

331. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 99 in a suitable package.

332. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 113 in a suitable package.

333. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 117 in a suitable package.

334. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 133 in a suitable package.

335. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 193 in a suitable package.

336. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 223 in a suitable package.

337. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 252 in a suitable package.

338. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 284 in a suitable package.

339. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 268 in a suitable package.

340. (Previously Presented) A polynucleotide of any of claims 60-73 wherein said polynucleotide encodes a polypeptide having a sequence comprising at least 10 contiguous amino acids from an HCV1 polyprotein.

341. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 3.

342. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 62A.

343. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a

detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 89.

344. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.
345. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.
346. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 89.
347. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 14.
348. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of Figure 58.
349. (Previously Presented) A method according to any of claims 344-348 wherein said selected samples comprise said polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said polynucleotide and said contiguous

sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

350. Canceled.

351. (Previously Presented) A method according to claim 349 wherein said polynucleotide is detectable in a PCR assay.

352. (Previously Presented) A method according to claim 349 wherein said biological samples are blood.

353. Canceled.

354. (Previously Presented) A method according to claim 351 wherein said biological samples are blood.

355. (Previously Presented) A method according to claim 349 wherein said biological samples are plasma.

356. Canceled.

357. (Previously Presented) A method according to claim 351 wherein said biological samples are plasma.

358. (Previously Presented) A method according to claim 349 wherein said biological samples are sera.

359. Canceled.

360. (Previously Presented) A method according to claim 351 wherein said biological samples are sera.

361. (Previously Presented) A method according to claim 352 further comprising employing biological samples that are not selected for a preparation of blood-related products.

362. (Previously Presented) A method according to claim 355 further comprising employing biological samples that are not selected for a preparation of blood-related products.

363. (Previously Presented) A method according to claim 352 further comprising preparing polyclonal antibodies with selected biological samples.

364. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

365. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt- 11 cDNA library deposited as A TCC No. 40394.

366. (Previously Presented) A method according to claim 352 wherein the selecting is to identify an HCV positive sample for removal from the supply.

367. Canceled.

368. (Previously Presented) A method according to claim 354 wherein the selecting is to identify an HCV positive sample for removal from the supply.

369. (Previously Presented) A method according to claim 355 wherein the selecting is to identify an HCV positive sample for removal from the supply.

370. Canceled.

371. (Previously Presented) A method according to claim 357 wherein the selecting is to identify an HCV positive sample for removal from the supply.

372. (Previously Presented) A method according to claim 358 wherein the selecting is to identify an HCV positive sample for removal from the supply.

373. Canceled.

374. (Previously Presented) A method according to claim 360 wherein the selecting is to identify an HCV positive sample for removal from the supply.

375. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

376. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

377. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as A TCC No. 40394.

378. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.

379. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second

polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

380. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

381. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either strand of Figure 58.

382. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either stand of Figure 58.

383. (Previously Presented) A method according to any of claims 375, 377, 379, 381 wherein said selected samples comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence of nucleotides and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

384. (Previously Presented) A method according to any of claims 376, 378, 380, 382 wherein said selected samples do not comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

385. (Previously Presented) A method according to claim 383, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

386. (Previously Presented) A method according to claim 384, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

387. (Previously Presented) A method according to claim 383 wherein said first polynucleotide is detectable in a PCR assay.

388. (Previously Presented) A method according to 385, wherein said first polynucleotide is detectable in a PCR assay.

389. (Previously Presented) A method according to claim 384 wherein said first polynucleotide is not detectable in a PCR assay.

390. (Previously Presented) A method according to claim 386 wherein said first polynucleotide is not detectable in a PCR assay.

391. (Previously Presented) A method according to any of claims 375-382 wherein said biological samples are blood.

392. (Previously Presented) A method according to claim 383 wherein said biological samples are blood.

393. (Previously Presented) A method according to claim 384 wherein said biological samples are blood.

394. (Previously Presented) A method according to claim 385 wherein said biological samples are blood.

395. (Previously Presented) A method according to claim 386 wherein said biological samples are blood.

396. (Previously Presented) A method according to claim 387 wherein said biological samples are blood.

397. (Previously Presented) A method according to claim 388 wherein said biological samples are blood.

398. (Previously Presented) A method according to claim 389 wherein said biological samples are blood.

399. (Previously Presented) A method according to claim 390 wherein said biological samples are blood.

400. (Previously Presented) A method according to any of claims 375-382 wherein said biological samples are plasma.

401. (Previously Presented) A method according to claim 383 wherein said biological samples are plasma.

402. (Previously Presented) A method according to claim 384 wherein said biological samples are plasma.

403. (Previously Presented) A method according to claim 385 wherein said biological samples are plasma.

404. (Previously Presented) A method according to claim 386 wherein said biological samples are plasma.

405. (Previously Presented) A method according to claim 387 wherein said biological samples are plasma.

406. (Previously Presented) A method according to claim 388 wherein said biological samples are plasma.

407. (Previously Presented) A method according to claim 389 wherein said biological samples are plasma.

408. (Previously Presented) A method according to claim 390 wherein said biological samples are plasma.

409. (Previously Presented) A method according to any of claims 375-382 wherein said biological samples are sera.

410. (Previously Presented) A method according to claim 383 wherein said biological samples are sera.

411. (Previously Presented) A method according to claim 384 wherein said biological samples are sera.

412. (Previously Presented) A method according to claim 385 wherein said biological samples are sera.

413. (Previously Presented) A method according to claim 386 wherein said biological samples are sera.

414. (Previously Presented) A method according to claim 387 wherein said biological samples are sera.

415. (Previously Presented) A method according to claim 388 wherein said biological samples are sera.

416. (Previously Presented) A method according to claim 389 wherein said biological samples are sera.

417. (Previously Presented) A method according to claim 390 wherein said biological samples are sera.

418. (Previously Presented) A method according to any of claims 375, 377, 379 or 381 further comprising employing biological samples that are not selected for a preparation of blood-related products.

419. (Previously Presented) A method according to claim 383 further comprising employing biological samples that are not selected for a preparation of blood-related products.

420. (Previously Presented) A method according to claim 385 further comprising employing biological samples that are not selected for a preparation of blood-related products.

421. (Previously Presented) A method according to claim 387 further comprising employing biological samples that are not selected for a preparation of blood-related products.
422. (Previously Presented) A method according to claim 388 further comprising employing biological samples that are not selected for a preparation of blood-related products.
423. (Previously Presented) A method according to any of claims 376, 378, 380 or 382 further comprising employing biological samples that are selected for a preparation of blood-related products.
424. (Previously Presented) A method according to claim 384 further comprising employing biological samples that are selected for a preparation of blood-related products.
425. (Previously Presented) A method according to claim 386 further comprising employing biological samples that are not selected for a preparation of blood-related products.
426. (Previously Presented) A method according to claim 389 further comprising employing biological samples that are not selected for a preparation of blood-related products.
427. (Previously Presented) A method according to claim 390 further comprising employing biological samples that are not selected for a preparation of blood-related products.
428. (Previously Presented) A method according to any of claims 376, 378, 380 or 382 wherein said selected samples are supply samples for preparation of blood products.
429. (Previously Presented) A method according to claim 384 wherein said selected samples are supply sample for preparation of blood products.
430. (Previously Presented) A method according to claim 386 wherein said selected samples are supply sample for preparation of blood products.
431. (Previously Presented) A method according to claim 389 wherein said selected samples are supply sample for preparation of blood products.
432. (Previously Presented) A method according to claim 390 wherein said selected samples are supply sample for preparation of blood products.

433. (Previously Presented) A method according to any of claims 375, 377, 379 or 381 wherein said samples that are not selected are supply samples for preparation of blood products.

434. (Previously Presented) A method according to claim 383 wherein said samples that are not selected are supply samples for preparation of blood products.

435. (Previously Presented) A method according to claim 385 wherein said samples that are not selected are supply samples for preparation of blood products.

436. (Previously Presented) A method according to claim 387 wherein said samples that are not selected are supply samples for preparation of blood products.

437. (Previously Presented) A method according to claim 388 wherein said samples that are not selected are supply samples for preparation of blood products.

Please add the following new claims:

438. (New) A method according to any of claims 341-348, 364 or 365 wherein said polynucleotide is detectable in a PCR assay.

439. (New) A method according to claim 438 wherein said biological samples are blood.

440. (New) A method according to claim 438 wherein said biological samples are plasma.

441. (New) A method according to claim 438 wherein said biological samples are sera.

442. (New) A method according to claim 439 wherein the selecting is to identify an HCV positive sample for removal from the supply.

443. (New) A method according to claim 440 wherein the selecting is to identify an HCV positive sample for removal from the supply.

444. (New) A method according to claim 441 wherein the selecting is to identify an HCV positive sample for removal from the supply.

445. (New) A method according to claims 344-348, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

446. (New) A method according to claim 349 wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

447. (New) A method according to claim 445 wherein said polynucleotide is detectable in a PCR assay.

448. (New) A method according to claim 446 wherein said polynucleotide is detectable in a PCR assay.

449. (New) A method according to claim 445 wherein said biological samples are blood.

450. (New) A method according to claim 446 wherein said biological samples are blood.

451. (New) A method according to claim 445 wherein said biological samples are plasma.

452. (New) A method according to claim 446 wherein said biological samples are plasma.

453. (New) A method according to claim 445 wherein said biological samples are sera.

454. (New) A method according to claim 446 wherein said biological samples are sera.

455. (New) A method according to claim 447 wherein said biological samples are blood.

456. (New) A method according to claim 448 wherein said biological samples are blood.

457. (New) A method according to claim 447 wherein said biological samples are sera.

458. (New) A method according to claim 448 wherein said biological samples are sera.

459. (New) A method according to claim 447 wherein said biological samples are plasma.

460. (New) A method according to claim 448 wherein said biological samples are plasma.

461. (New) A method according to claim 445 further comprising employing biological samples that are not selected for a preparation of blood-related products.
462. (New) A method according to claim 446 further comprising employing biological samples that are not selected for a preparation of blood-related products.
463. (New) A method according to claim 447 further comprising employing biological samples that are not selected for a preparation of blood-related products.
464. (New) A method according to claim 448 further comprising employing biological samples that are not selected for a preparation of blood-related products.
465. (New) A method according to claim 445 wherein said samples that are not selected are supply samples for preparation of blood products.
466. (New) A method according to claim 446 wherein said samples that are not selected are supply samples for preparation of blood products.
467. (New) A method according to claim 447 wherein said samples that are not selected are supply samples for preparation of blood products.
468. (New) A method according to claim 448 wherein said samples that are not selected are supply samples for preparation of blood products.
469. (New) A method according to claim 358 further comprising employing biological samples that are not selected for a preparation of blood-related products.